The number of retraction notices of papers co-authored by Silvia Bulfone-Paus is up to eight.
The Journal of Leukocyte Biology, which was apparently the first to announce they had accepted a retraction, has published its notice: Continue reading Two more Bulfone-Paus retraction notices appear
Since we first wrote about the travails of Spirocor’s bedside, noninvasive test for coronary artery disease, we’ve been trying, without much success, to find out more information.
But as they say about every dog, our day has come.
As we initially reported, Ron Waksman, a prominent Washington, D.C. cardiologist and editor-in-chief of Cardiovascular and Revascularization Medicine, was first author of one of two papers about the Spirocor technology that were published in 2010. The other, by Shiyovich, et al, was retracted earlier this month by the American Journal of the Medical Sciences, which triggered our interest in this case.
At the time, we couldn’t find any evidence that Waksman’s article had been retracted, and Waksman has not responded to multiple requests for comment. Today we spoke with Kate Coons, the journal’s managing editor, who told us that the authors had sought a retraction for the article, “An innovative noninvasive respiratory stress test indicates significant coronary artery disease,” in December, and that it had posted one on its website on Jan. 6 of this year. It will be in print in an upcoming issue.
The notice is not available on Medline, but it can be found on ScienceDirect: Continue reading More on SPIROCOR noninvasive heart disease test: Second retraction (in fact the first) says little
Another retraction notice for a paper by Silvia Bulfone-Paus and colleagues has appeared, this one for a 2007 paper in the Journal of Biological Chemistry (JBC), “Soluble IL-15Rα is generated by alternative splicing or proteolytic cleavage and forms functional complexes with Il-15.”
This is the sixth retraction notice of a promised 12 in several journals. The original paper has been cited 37 times, according to Thomson Scientific’s Web of Knowledge.
Some of the notices have gone into great detail about what was wrong with the original papers, and journals have even allowed the team to declare that some of the results had been replicated. One simply said there had been misconduct.
Then there’s this one: Continue reading Bulfone-Paus retraction notice appears in the Journal of Biological Chemistry
Last week, we reported that the Scandinavian Journal of Immunology had noted that a 2002 paper by Silvia Bulfone-Paus and colleagues had been retracted, but hadn’t yet published the retraction notice. A commenter tipped us off this week that the notice is out: Continue reading Scandinavian Journal of Immunology publishes Bulfone-Paus retraction notice
A retraction in an obscure journal. An equally obscure retraction notice. An Israeli company with no web presence. Conflicts of interest involving authors and editors.
That’s what we’ve uncovered so far after noticing the other day that the American Journal of the Medical Sciences (AJMS) had retracted a May 2010 article by a group of Israeli heart doctors led by Arthur Shiyovich, of Barzilai Medical Center in Ashkelon.
The paper described promising results in a study of a new test for diagnosing coronary artery disease at the bedside by measuring aspects of a patient’s pulse at the fingertip.
As AJMS editor David Ploth told us, the approach had seemed “kind of innovative” to him, so he’d accepted the manuscript: “It seemed like it might have some applicability.”
Ploth was therefore surprised sometime later to receive a letter from the authors requesting that the journal retract their paper. According to the journal: Continue reading Tangled leads: Cardiac study retraction reveals a company’s stopped trials, and lots of questions
The retraction notices for papers by Silvia Bulfone-Paus continue to appear. Yesterday, the Journal of Immunology posted notices for these three previously accepted retractions by the researcher, work at whose Borstel Centre lab is under investigation for misconduct.
Something was fishy at China Normal University. According to the journal Anti-Cancer Drugs, a 2010 paper by researchers at the Beijing school — “3,30′-Diindolylmethane negatively regulates Cdc25A and induces a G2/M arrest by modulation of microRNA21 in human breast cancer cells” — turned out to have suffered from an unfortunate anomaly. According to the retraction notice: Continue reading We wrote what? Breast cancer paper falls to rogue author
There was more news today about papers co-authored by Silvia Bulfone-Paus, whose lab at Research Centre Borstel has been under investigation for scientific misconduct.
The EMBO Journal, which we reported last month had accepted the retraction of a 2005 Bulfone-Paus paper that has been cited 37 times, published the retraction notice for the study today:
Eight of the authors (ZO, LT, UM, PB, CB, DA, RP and SB-P) wish to retract this paper, following an independent formal investigation initiated by the Research Center Borstel into scientific misconduct (see http://www.fz-borstel.de/cms/index.php?id=1). The investigation concluded that multiple figures contained PCR and western blot duplications and possible other manipulations (Figures 2A, 3A, 4A, 5, 7A and 7C, Supplementary Figures S1A, S2A and S2B, unconfirmed: Figure 1C). The above signed declare that Vadim Budagian and Elena Bulanova conducted these experiments and generated the figures. The authors declare that key experiments presented in the majority of these figures were recently reproduced and that the results confirmed the experimental data and the conclusions drawn from them. However, due to these unacceptable irregularities, the listed authors retract this paper in its entirety and regret any adverse consequences that may have resulted from its publication. Vadim Budagian and Elena Bulanova declined to sign the retraction.
As retraction notices go, this is better than average, we must say. It’s certainly better than the many opaque notices we’ve seen. But there’s a line in there that Karin Wiebauer and David Hardman, both of whom brought the notice to our attention, found curious: Continue reading In retraction notice, Bulfone-Paus “declares” data and conclusions confirmed; journals accept six more retractions
With the third retraction of a paper by Anil Potti this weekend, plus details of various investigations dribbling out, we decided to check in with the world’s two leading medical journals about whether they planned to retract the papers of Potti’s they’d published.
JAMA published two papers by Potti and colleagues: One, “Gene Expression Signatures, Clinicopathological Features, and Individualized Therapy in Breast Cancer,” appeared in 2008. It has been cited 51 times, according to Thomson Scientific’s Web of Knowledge, and was the subject of two letters. In one, a correspondent expressed concerns about the lack of information in the study about Continue reading No Potti retractions on the horizon from JAMA, NEJM
Early in December, as the house of cards that is Anil Potti‘s publication record started to really collapse, we called attention to a paper in The Lancet Oncology that had already been the subject of a correction and Expression of Concern in July of last year. Today, the journal officially retracted the paper, “Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.” The paper was cited more than 100 times, according to Google Scholar.
The retraction notice: Continue reading Lancet Oncology retracts previously questioned Anil Potti paper